Breast cancer is the most common malignancy and leading cause of death among women. Early and accurate detection is crucial for improving outcomes. Ultrasound (US) is widely used for its non-invasiveness, affordability, and accessibility, serving as a valuable first-line diagnostic tool for breast examination. Recent advancements in nanomedicine are enhancing US diagnostics, allowing for personalized evaluations based on the molecular phenotype of tumors. This review covers the current state of US diagnosis for breast cancer and recent advancements in US contrast agents for molecular diagnostics, which are still under preclinical study.
0
